Last reviewed · How we verify
clofarabine, fludarabine and busulfan, CloFluBu
clofarabine, fludarabine and busulfan, CloFluBu is a Chemotherapy combination (nucleoside analogs + alkylating agent) Small molecule drug developed by Vastra Gotaland Region. It is currently in Phase 3 development for Conditioning regimen for hematopoietic stem cell transplantation in acute leukemias and lymphomas. Also known as: CloFluBu.
CloFluBu is a combination chemotherapy regimen that inhibits DNA synthesis and repair through three nucleoside analogs, used as a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation.
CloFluBu is a combination chemotherapy regimen that inhibits DNA synthesis and repair through three nucleoside analogs, used as a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation. Used for Conditioning regimen for hematopoietic stem cell transplantation in acute leukemias and lymphomas.
At a glance
| Generic name | clofarabine, fludarabine and busulfan, CloFluBu |
|---|---|
| Also known as | CloFluBu |
| Sponsor | Vastra Gotaland Region |
| Drug class | Chemotherapy combination (nucleoside analogs + alkylating agent) |
| Target | DNA synthesis and repair pathways; ribonucleotide reductase; DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Clofarabine and fludarabine are purine nucleoside analogs that inhibit ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells. Busulfan is an alkylating agent that cross-links DNA. Together, this triple-agent combination provides intensive myeloablation to eliminate malignant and host bone marrow cells before stem cell transplantation.
Approved indications
- Conditioning regimen for hematopoietic stem cell transplantation in acute leukemias and lymphomas
Common side effects
- Myelosuppression
- Mucositis
- Nausea and vomiting
- Hepatotoxicity
- Infection
- Hemorrhage
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clofarabine, fludarabine and busulfan, CloFluBu CI brief — competitive landscape report
- clofarabine, fludarabine and busulfan, CloFluBu updates RSS · CI watch RSS
- Vastra Gotaland Region portfolio CI
Frequently asked questions about clofarabine, fludarabine and busulfan, CloFluBu
What is clofarabine, fludarabine and busulfan, CloFluBu?
How does clofarabine, fludarabine and busulfan, CloFluBu work?
What is clofarabine, fludarabine and busulfan, CloFluBu used for?
Who makes clofarabine, fludarabine and busulfan, CloFluBu?
Is clofarabine, fludarabine and busulfan, CloFluBu also known as anything else?
What drug class is clofarabine, fludarabine and busulfan, CloFluBu in?
What development phase is clofarabine, fludarabine and busulfan, CloFluBu in?
What are the side effects of clofarabine, fludarabine and busulfan, CloFluBu?
What does clofarabine, fludarabine and busulfan, CloFluBu target?
Related
- Drug class: All Chemotherapy combination (nucleoside analogs + alkylating agent) drugs
- Target: All drugs targeting DNA synthesis and repair pathways; ribonucleotide reductase; DNA polymerase
- Manufacturer: Vastra Gotaland Region — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Conditioning regimen for hematopoietic stem cell transplantation in acute leukemias and lymphomas
- Also known as: CloFluBu
- Compare: clofarabine, fludarabine and busulfan, CloFluBu vs similar drugs
- Pricing: clofarabine, fludarabine and busulfan, CloFluBu cost, discount & access